Top 15 Fastest-Growing Profitable Healthcare Stocks
Marvin's rules found 15 profitable Healthcare companies with strong Overall scores, ranked by last-fiscal-year revenue growth. AnaptysBio, Delcath Systems and Eton Pharmaceuticals lead the list.
Fast revenue growth means a company sold much more in its last fiscal year than the year before. This list looks only at Healthcare companies that are profitable and have a solid Overall score from Marvin, then puts the fastest growers first. The sector covers drug makers, biotechnology firms, medical device makers, diagnostics, care facilities and health information services.
Growth is only one part of the picture. A company can grow quickly from a small base, and a single year does not show what comes next. Each pick below pairs its growth with margins, returns and debt where those figures are available, so you can see how much profit sits behind the sales gains.
Some figures are missing for certain companies, and a few have thin or near-zero margins. Each description names an honest caution. Treat the list as a starting point for your own research, not as advice.
The list
How Marvin ranked these stocks
Marvin started with Healthcare companies above a minimum size, kept only profitable ones with an Overall score at or above a set threshold, and allowed at most four per industry. They are ranked by revenue growth in the last fiscal year, fastest first. Marvin's scores run from zero to one hundred and compare each company only with others in its own industry, so a high score does not mean it beats companies in other industries. Data is as of late 2026.
Companies above about $300 million in size, ranked by Marvin scores (0-100, relative to each company's own industry). The Healthcare sector, fastest last-fiscal-year revenue growth first, among profitable companies with an Overall score of at least 55; at most 4 per industry.
The stocks, one by one
AnaptysBio, Inc. ANAB
AnaptysBio grew revenue by 157.0% and posted an operating margin of 90.8%, meaning very fast sales growth with a large profit left from each dollar of revenue. Caution: its return on equity of 1849.1% is unusually large, and free cash flow and gross margin figures are missing.
Delcath Systems, Inc. DCTH
Delcath Systems grew revenue by 129.1% and keeps a gross margin of 87.1%, so most sales revenue is left after direct costs. Its free cash flow margin is 18.3%. Caution: the operating margin of -1.9% is just below break-even, and debt data is missing.
Eton Pharmaceuticals, Inc. ETON
Eton Pharmaceuticals roughly doubled revenue, with growth of 104.9%, and earns an operating margin of 15.4% and a free cash flow margin of 14.0%. Debt-to-equity of 0.63 is moderate. Caution: the gross margin of 57.9% is lower than many others here.
BillionToOne, Inc. BLLN
BillionToOne grew revenue by 100.0%, with an operating margin of 10.9% and debt-to-equity of just 0.27, which is low. Caution: profit is still modest, with a free cash flow margin of 8.3% and return on equity of 7.0%.
TG Therapeutics, Inc. TGTX
TG Therapeutics grew revenue by 87.3% and has a gross margin of 82.4%, so most revenue is left after direct costs. Operating margin is 17.1%. Caution: free cash flow margin is only 2.2%, and debt-to-equity of 1.25 is higher than many peers on this list.
Nutex Health, Inc. NUTX
Nutex Health pairs revenue growth of 82.4% with a strong operating margin of 40.6% and a free cash flow margin of 32.4%. Its Overall score is 97. Caution: debt-to-equity of 0.88 means borrowing plays a real role in its finances.
Alnylam Pharmaceuticals, Inc. ALNY
Alnylam Pharmaceuticals grew revenue by 65.2%, has a gross margin of 79.8%, and turns an operating margin of 20.8% into a free cash flow margin of 17.1%. Caution: its Overall score of 57 is more modest here, and debt data is missing.
Rigel Pharmaceuticals, Inc. RIGL
Rigel Pharmaceuticals grew revenue by 64.1% with a gross margin of 91.4% and an operating margin of 31.5%. Return on equity is 75.7%, and its Overall score is 97. Caution: free cash flow and debt figures are not available, so cash generation is unclear.
Astrana Health, Inc. ASTH
Astrana Health grew revenue by 56.4%, though profits are thin: operating margin is 2.6% and free cash flow margin is 2.5%. Caution: little of each sales dollar becomes profit, and debt-to-equity of 1.18 is on the higher side.
Omada Health OMDA
Omada Health grew revenue by 53.2%, has a gross margin of 68.2%, and produced a free cash flow margin of 7.3%. Caution: its operating margin of -0.1% is slightly below zero and return on equity is only 1.7%, so profits are very thin.
Hinge Health, Inc. HNGE
Hinge Health grew revenue by 50.6%, with a gross margin of 84.5%, a free cash flow margin of 40.3%, and very low debt-to-equity of 0.02. Caution: its operating margin of 13.0% is much lower than its cash margin.
Eli Lilly and Company LLY
Eli Lilly and Company grew revenue by 44.7%, has a gross margin of 83.4%, and earns a return on equity of 78.8%. Its quality score is 94. Caution: debt-to-equity of 1.62 is relatively high, and operating and free cash flow margins are missing.
ANI Pharmaceuticals, Inc. ANIP
ANI Pharmaceuticals grew revenue by 43.8%, with an operating margin of 15.4%, a free cash flow margin of 17.7%, and moderate debt-to-equity of 0.50. Its Overall score is 96. Caution: gross margin data is missing, and growth is slower than the leaders.
TransMedics Group, Inc. TMDX
TransMedics Group grew revenue by 37.1%, with an operating margin of 12.2%, a free cash flow margin of 11.8%, and a gross margin of 58.7%. Caution: margins are decent but not outstanding, and debt-to-equity data is missing.
The Pennant Group, Inc. PNTG
The Pennant Group grew revenue by 36.3%, the slowest pace on this list but still fast. Caution: its operating margin of 5.6% and free cash flow margin of 3.1% are thin, and debt-to-equity is 1.21. Return on equity is 8.0%.
Common questions
What does revenue growth tell me about a company?
It shows how much a company's sales rose in its last fiscal year compared with the year before. Fast growth can signal rising demand, but it says nothing alone about profit, debt or whether the pace will continue.
Why do some companies on the list have missing figures?
Not every company reports every measure in a way Marvin can compare, so some margins or debt ratios are unavailable. The descriptions only use figures that exist, and they flag missing ones as a caution.
Does a high Overall score mean a company is a better investment?
No. Marvin's scores only describe how a company compares with others in its own industry today. A score of this kind is not a forecast, and companies in different industries are not directly comparable.
Keep reading
- Top 15 Healthcare Stocks Right Now, Ranked by Marvin Scores
- Top 15 Healthcare Stocks by Marvin Opportunity Score
- Top 20 Medical Stocks Ranked by Marvin Scores
- Top 15 Healthcare Companies With the Strongest Businesses
Free account. Build your own AI-made watchlists, follow Marvin's scores and share lists.
Create a free account
Marvin's scores (0-100) compare each company with others in its industry today. Growth and margin figures come from SEC filings. This is general information, not personal investment advice or a recommendation to buy or sell anything. Do your own research.